UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   November 16, 2020

 

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

New York

0-12305

13-3044880

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)


24 Carpenter Road, Chester, New York

10918

(Address of principal executive offices)

(Zip Code)


Registrant’s telephone number, including area code   (845) 469-2042

 

not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, $0.01 par value

KRMD

The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 



ITEM 8.01 OTHER EVENTS.


On November 16, 2020, the Board of Directors (the “Board”) of Repro Med Systems, Inc. d/b/a KORU Medical Systems (the “Company”) authorized and approved a stock repurchase program for up to $10 million of the currently outstanding shares of the Company’s common stock through December 31, 2021. Under the stock repurchase program, the Company may repurchase shares in open market transactions at prevailing market prices, in privately negotiated transactions, or by other means in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934 (the “Exchange Act”). Purchases pursuant to the stock repurchase program will be at times and in amounts as determined appropriate by the Company and will depend on a number of factors, including price and general business and market conditions. The stock repurchase program replaces the Company’s previous stock repurchase program, which had been discontinued by management in June 2017.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.


(d) Exhibits.


Exhibit No. Description
   
99.1 Press release dated November 16, 2020



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

REPRO MED SYSTEMS, INC.
(Registrant)

 

 

 

Date:  November 16, 2020

By:

/s/ Karen Fisher

 

Karen Fisher
Chief Financial Officer


- 2 -


KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more KORU Medical Systems Charts.
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more KORU Medical Systems Charts.